IL1A and neoplasm: These findings suggest that inhibition of IL-1α expression and activity in PDAC will drastically decrease the levels of inflammatory factors in CAFs, and reducing and/or neutralizing the effects of IL-1α could have the potential to reduce tumor spread and improve the clinical outcome for the patients [5], [9].